BRIGHT MINDS BIOSCIENCES INC (DRUG)
Health Care · Biopharmaceuticals / Clinical-stage drug development · NASDAQ
Bright Minds Biosciences is a clinical-stage biotechnology company developing next-generation serotonin-targeting therapies for neuropsychiatric, epilepsy, and pain conditions.
What BRIGHT MINDS BIOSCIENCES INC does
Bright Minds Biosciences Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics to treat neuropsychiatric disorders, epilepsy, and pain. The company utilizes a drug discovery platform to create next-generation serotonin receptor agonists designed to improve upon existing therapies.
Themes: neuropsychiatry, epilepsy research, chronic pain therapy, CNS drug development
Fundamentals
- Price$77.42 as of 2026-08-21 close
- Market cap$781M as of 2026-08-24
- 1-year return+83.8% 2025-08-21 close $42.13 → 2026-08-21 close $77.42
- P/En/a earnings data not available
- ROE-20.6% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Beta1.95 as of 2026-08-24
- Last reported earningsn/a no confirmed date — as a foreign private issuer it reports on Form 6-K, which carries no earnings item code
How DRUG compares in its sector
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How BRIGHT MINDS BIOSCIENCES INC looks technically
BRIGHT MINDS BIOSCIENCES INC (DRUG) is trading 1.0% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed below its 200-day average about 24 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 17, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 50, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 1 trading day ago (its momentum flipped negative). It made a new 20-day high about 3 trading days ago. It is 37.4% below its highest point of the past year.
Trend
9
| Distance from the 200-day | it is trading 1.0% above its 200-day average, the long-term trend line — a longer-term uptrend | +1.1% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $72.32 | $72.32 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $76.62 | $76.62 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 7 calendar days ago — the swings before that are what the structure reading is measured on | 7 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes below 75.285. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible upward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 24 trading days ago — a "death cross", a bearish long-term signal | 24 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 1.0% above | +1.1% |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 17, below the 25 that marks a real trend) | 16.8 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 50, neither overbought (above 70) nor oversold (below 30) | 50.2 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($74.20 to $87.00) — its "stochastic" reading is 25 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 25.2 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 1 trading day ago (its momentum flipped negative) | 1 session |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $123.75 | $123.75 |
|---|---|---|
| From the 52-week high | it is 37.4% below its 52-week high (its highest price of the past year) | -37.4% |
| Above the 52-week low | it is 103.7% above its 52-week low (its lowest price of the past year) | +103.7% |
| Below the 52-week high | it is 37.4% below its highest point of the past year | 37.4% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day low about 48 trading days ago | 48 sessions |
| All-time high | its highest closing price on record is $123.75 (set on 2026-01-06) | $123.75 |
| Given back of the 52-week move | over the past year its closes ranged ($38.80 to $95.98), and it has given back roughly a third of its rise from last year’s low — 32% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $58.81 to $60.64. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 32.5% |
| From the all-time high | it is 37.4% below its all-time high | -37.4% |
| Nearest price level | it is sitting right on a support level at $77.41 — a price it turned at twice since 2025-12-18, most recently on 2026-03-25. Since 2024-10-15 it has 10 such levels below the current price and 2 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -0.0% |
| All-time low | its lowest closing price on record is $0.93 (set on 2024-04-30) | $0.93 |
| Above the all-time low | it is 8224.7% above its all-time low | +8,225% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 79% of it) | 21st percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $4.13 between its high and its low — about 5.3% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $4.13 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $70.08 and $85.23 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $70.08 – $77.66 – $85.23 |
| Typical daily range (% of price) | its price moves about 5.3% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.3% |
| Stretch from the 200-day average | it is trading 0.2 daily ranges above its 200-day average price (1.1% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 0.2 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.79× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 0.7% since the prior reading | +0.7% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
1
| Since a bullish engulfing | 4 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 4 sessions ago |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-08-21 0.4% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.4% |
|---|---|---|
| Gap filled | a 2.1% gap up opened on 2026-08-19 has been "filled" 2 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 2 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 2 sessions in a row, a -8.64% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 2 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 2.2 percentage points (the stock gained 0.2% while the market gained 2.3%) | -2.2% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 10.1 percentage points (the stock lost 7.0% while the market gained 3.1%) | -10.1% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 20.5 percentage points (the stock lost 9.4% while the market gained 11.1%) | -20.5% |
| vs market, 12 months | over the past 12 months this stock beat the market by 63.3 percentage points (the stock gained 83.8% while the market gained 20.5%) | +63.3% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: trading above its 200-day average, a fresh 20-day high, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, MACD momentum is negative, lagging the market over 6 months — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 4.3% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 6.2% of the share price. | +4.3% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is sitting right on the average price paid so far this year, so the typical buyer over that stretch is roughly break-even. That average is $77.33 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | +0.1% |
|---|
Price levels it has turned at before
DRUG last closed at $77.42 on 2026-08-21. Since 2024-10-15 it has turned at 10 prices below its last close and 2 above; the 3 nearest below and the 2 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $77.41 | Support | at the last close | turned there twice · 2025-12-18 to 2026-03-25 |
| $79.03 | Resistance | 2.1% above the last close | turned there twice · 2026-07-09 to 2026-07-17 |
| $72.18 | Support | 6.8% below the last close | turned there three times · 2026-01-05 to 2026-05-18 |
| $68.91 | Support | 11.0% below the last close | turned there twice · 2026-03-12 to 2026-07-29 |
| $91.80 | Resistance | 18.6% above the last close | turned there three times · 2026-02-24 to 2026-05-27 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes below $75.28.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $89.48 and $98.26 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close below $75.28.
This reading has stood for 1 trading day, since 2026-08-21.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Near 200-day moving-average support · Trading above the 200-day moving average · Recent death cross (50-day crossed below 200-day) · Pulled back from the 12-month high · Broke out to a new 20-day high · MACD just crossed bearish (12/26/9) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.14 mean, 1=Strong Buy…5=Strong Sell) — 3 analysts
- Mean price target$169.89 range $144.57 – $220.09; median $144.99
Analyst estimates, as of 2026-08-19. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for DRUG
- Consensus EPS estimate-C$1.70 next reporting period, as of 2026-08-19
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical development risk — as a drug development company, success depends on advancing candidates through trials with uncertain outcomes","Capital intensity — biopharmaceutical development requires significant ongoing funding; with a ~$970M market cap and negative price return, funding availability and burn rate are material risks","Market-specific risk — the -74.8% one-year stock decline suggests significant investor concern about pipeline progress, clinical trial results, or competitive position"]
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days.
- Last 180 days0 buys · 1 sell ($10M) — 1 selling insider
Most recent open-market transaction: 2026-04-28. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about DRUG's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
3 institutional 13F filers reported holding DRUG as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 3
- Reported shares held 730,991
- Reported value $53,340,428
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 2 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
DRUG had 890,847 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
Short interest as a percent of shares outstanding is not shown for DRUG because its US listing is a depositary receipt and we have not yet read how many ordinary shares each receipt represents, so the share base cannot be converted. The reported figures above are unaffected.
- Reported short interest (shares) 890,847
- Prior settlement (shares) 955,805
- Reported change -6.8%
- Days to cover (reported) 4.05
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Frequently asked questions
What does BRIGHT MINDS BIOSCIENCES INC (DRUG) do?
Bright Minds Biosciences Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics to treat neuropsychiatric disorders, epilepsy, and pain. The company utilizes a drug discovery platform to create next-generation serotonin receptor agonists designed to improve upon existing therapies.
What sector is BRIGHT MINDS BIOSCIENCES INC (DRUG) in?
BRIGHT MINDS BIOSCIENCES INC (DRUG) is classified in the Health Care sector. Its industry is Biopharmaceuticals / Clinical-stage drug development. It trades on NASDAQ.
Is BRIGHT MINDS BIOSCIENCES INC (DRUG) overbought or oversold right now?
BRIGHT MINDS BIOSCIENCES INC (DRUG) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 50, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on DRUG come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.